Clinics in Dermatology
Volume 26, Issue 5 , Pages 509-514, September 2008

Efalizumab in the treatment of psoriasis: mode of action, clinical indications, efficacy, and safety

  • Michael P. Schön, MD

      Affiliations

    • Rudolf Virchow Center, Deutsche Forschungsgemeinschaft Research Center for Experimental Biomedicine, Versbacher Str 9, 97078 Würzburg, Germany
    • Department of Dermatology, University of Würzburg, Josef-Schneider-Straße 2, 97080 Würzburg, Germany
    • Department of Dermatology and Venerology, University Medical Center Göttingen, von-Siebold Str 3, 37075 Göttingen, Germany
    • Corresponding Author InformationDepartment of Dermatology and Venerology, University Medical Center Göttingen, von-Siebold Str 3, 37075 Göttingen, Germany. Tel.: +49 551 39 6401.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0738-081X(07)00250-7

doi:10.1016/j.clindermatol.2007.10.027

Clinics in Dermatology
Volume 26, Issue 5 , Pages 509-514, September 2008

Article Tools